VVOS Share Price Performance

VVOS Community Fair Values

AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Acquisitions And Sleep Center Integrations Will Expand Future Markets
Key Takeaways Pivoting from dentist-led distribution to integrating with sleep medicine providers should boost margins, revenue growth, and capture more value from the sleep apnea market. Recent acquisitions and new business model aim for profitability, reduced cash burn, and capitalize on industry consolidation through a scalable expansion strategy.
US$4.23
FV
22.6% overvalued intrinsic discount
12.50%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
about 1 month ago author updated this narrative

View all narratives

Recent VVOS News & Updates

No updates

Vivos Therapeutics, Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

Earnings per share (EPS): -1.91
Gross Margin: 58.73%
Net Profit Margin: -76.82%
Debt/Equity Ratio: 0%

View full report ›

Vivos Therapeutics, Inc. Competitors

View more competitors

About VVOS

Founded: 2016
Employees: 113
CEO: R. Huntsman
WebsiteView website: www.vivos.com

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

U.S. Market Performance

7 Days: -2.7%
3 Months: 10.7%
1 Year: 17.5%
Year to Date: 5.9%

Over the past 7 days, the market has dropped 2.7% with the Financials sector contributing the most to the decline. In the last year, the market is actually up 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›

💥 How Agentic AI Could Change Every Industry

Richard Bowman

August 2025

This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.

Last Week

Vivos Therapeutics Stock Price